Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

The Risk of Depression in a Large Huntington Disease Population Compared With Controls: Analysis of the Enroll-HD Registry Data
Movement Disorders
P1 - Poster Session 1 (8:00 AM-9:00 AM)
5-012

While high rates of depression have been reported in HD, real-world data on depression risk and risk factors in individuals with versus without HD by disease stage are incomplete.

To describe the risk of depression among individuals with Huntington disease (HD; manifest) versus non-HD registry controls utilizing Enroll-HD data.

Enroll-HD is a global observational registry for individuals with or at risk for HD, and their relatives. Data were collected annually (2013–31 October 2020; manifest, n=10,917; non-HD, n=4996). HD stage was estimated via Total Functional Capacity (TFC) score and Shoulson-Fahn staging: TFC 7–‍13/stage 1–‍2 (early), TFC 3–‍6/stage 3 (middle), TFC 0–‍2/stage 4–‍5 (late). Chorea severity was measured by Total Maximal Chorea (TMC) score (TMC 0–‍7/mild; TMC 8 –‍28/moderate-to-severe), and depression by the Problem Behavioral Assessment binary scale. Odds ratios (ORs) were estimated via a logistic regression model controlling for multiple risk factors. 

Early (OR, 1.84) and middle (1.45) TFC groups were associated with significantly higher risk of depression relative to the non-HD group (both P<.001), but not the late group (1.10; P>.25). Depression risk was lower in moderate-to-severe versus mild chorea (0.81, P<.001), and for higher versus lower education (0.84, P<.001). Depression risk was higher for the following (all P<.01): ages 31–‍60 versus ≤30 years (1.18), females (1.53), overweight versus normal weight (1.13), obese versus normal weight (1.19), antipsychotic agents use (1.27), antidepressant agents use (1.58), smoking (1.18), alcohol problems (1.26), and drug abuse (1.32).

Depression risk was higher in participants with versus without HD, with an increased risk during early HD stages, even after controlling for relevant risk factors for depression. These findings emphasize the need for attention to depression in early HD.

Authors/Disclosures
Nayla Chaijale
PRESENTER
Nayla Chaijale has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Shoshana Reshef, PhD (Teva Pharmaceutical Inc.) Dr. Reshef has received personal compensation for serving as an employee of Teva.
Gerald Smith, Other (Cytel) The institution of Mr. Smith has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Cytel Inc..
Ofir Harari, PhD (Cytel Inc.) The institution of Dr. Harari has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Cytel Inc..
Mark Forrest Gordon, MD, FAAN (Teva Pharmaceuticals) Dr. Gordon has received personal compensation for serving as an employee of Teva. Dr. Gordon has stock in Teva.
Rinat Ribalov (Teva Pharmaceuticals) Rinat Ribalov has received personal compensation for serving as an employee of TEVA.
Tamar Lengil, PhD Dr. Lengil has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Sam Leo, PharmD (Teva) Dr. Leo has received personal compensation for serving as an employee of Teva Pharmaceutical Industries.
Rosa Willock (HCD Economics) Ms. Willock has received personal compensation for serving as an employee of HCD Economics.
Jose Antonio Robles-Zurita, PhD (Universidad de Málaga) Dr. Robles-Zurita has received personal compensation for serving as an employee of HCD Economics. Dr. Robles-Zurita has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for HCD Economics.
Erin Furr-Stimming, MD, FAAN (University of Texas Health Science Center-Houston) Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Michael J. Fox Foundation. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva Pharmaceuticals. The institution of Dr. Furr-Stimming has received research support from Huntington's Disease Society of America. The institution of Dr. Furr-Stimming has received research support from Roche/Genetech. The institution of Dr. Furr-Stimming has received research support from Uniqure. The institution of Dr. Furr-Stimming has received research support from CHDI. The institution of Dr. Furr-Stimming has received research support from Huntington Study Group/Neurocrine. The institution of Dr. Furr-Stimming has received research support from NIH/University of Iowa. The institution of Dr. Furr-Stimming has received research support from Sage Therapeutics. Dr. Furr-Stimming has received publishing royalties from a publication relating to health care.
Victor W. Sung, MD (University of Alabama At Birmingham) Dr. Sung has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva Neuroscience. Dr. Sung has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Sung has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. Dr. Sung has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UniQure.